This study, conducted in a centralized cytotoxic drug preparation unit, analyzes the effectiveness of two closed system drug transfer devices (CSTDs) in reducing leakage during antineoplastic drug compounding. Wipe/pad samplings inside and outside the preparation area were taken during surveillance programs from 2016 to 2021. All samples were analyzed for gemcitabine (GEM) contamination. In 2016, the presence of GEM in some samples and the contamination of the operators'' gloves in the absence of apparent drug spilling suggested unsealed preparation systems. In subsequent monitoring, GEM was also evaluated in the vial access device and in the access port system to the intravenous therapy bag of Texium^TM/SmartSite^TM and Equashield^? II devices after the reconstitution and preparation steps of the drug. The next checks highlighted GEM dispersion after compounding using Texium^TM/SmartSite^TM, with positive samples ranging from 9 to 23%. In contrast, gemcitabine was not present at detectable levels in the Equashield^? II system in all of the evaluated samples. The Equashield^? II closed system seems effectively able to eliminate spills and leakage during gemcitabine compounding. Since drugs with different viscosities can have different effects on CSTDs, Equashield^? II needs to be considered with other antineoplastic drugs during a structured surveillance program.

Keywords: antineoplastic drugs; closed system drug transfer device; drug compounding; environmental monitoring; gemcitabine.

Similar articles

Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
Soefje S, Rickabaugh K, Rajkumar R, Wall KP. Soefje S, et al. Int J Pharm Compd. 2021 Nov-Dec;25(6):515-522. Int J Pharm Compd. 2021. PMID: 34807847
Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
Soefje S, Rickabaugh K, Rajkumar R, Wall KP. Soefje S, et al. Int J Pharm Compd. 2022 Jan-Feb;26(1):72-79. Int J Pharm Compd. 2022. PMID: 35081047
Comparison of closed system transfer devices for turnaround time and ease of use.
Nurgat ZA, Lawrence M, Elhassan TA, Al Nahedh M, Ashour M, Alaboura D, Al-Jazairi AS, Al-Jedai A. Nurgat ZA, et al. J Oncol Pharm Pract. 2019 Jul;25(5):1142-1151. doi: 10.1177/1078155218781900. Epub 2018 Jun 29. J Oncol Pharm Pract. 2019. PMID: 29958506
Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs.
Forshay CM, Streeter SO, Salch SA, Eckel SF. Forshay CM, et al. J Oncol Pharm Pract. 2019 Jul;25(5):1160-1166. doi: 10.1177/1078155218787256. Epub 2018 Jul 24. J Oncol Pharm Pract. 2019. PMID: 30041583
Safe Cytotoxic Drug Preparation Using Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal).
Garrigue P, Montana M, Ventre C, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Garrigue P, et al. Int J Pharm Compd. 2016 Mar-Apr;20(2):148-54. Int J Pharm Compd. 2016. PMID: 27323425

Effectiveness of Closed System Drug Transfer Devices in Reducing Leakage during Antineoplastic Drugs Compounding

Abstract

Conflict of interest statement

Similar articles